Genenta Science S.p.A.
No SEC Form 4 filings for $GNTA in the last 30 days.
See all $GNTA insider activity →Genenta (GNTA) announced that its investment, Sòphia High Tech, contributed to the VEGA-C rocket's successful launch, which carried two Earth observation satellites. The Spring Assembly, produced by Sòphia HT, is crucial for stage separation. Genenta is evolving into Saentra Forge, focusing on aerospace and defense.
Genenta Science (Nasdaq: GNTA) said its backed Italian firm Sòphia High Tech is unveiling ROMAN, a robotic arm for inspection and maintenance inside the RFX-mod2 nuclear fusion machine, which can reach about 20 million °C. ROMAN can remove and reinstall graphite tiles and perform visual inspection and cleaning, developed with DII (Univ. Federico II) and Consorzio RFX.
Genenta-backed Sòphia High Tech (Italian aerospace and defense) announced ROMAN, a robotic arm for remote inspection and maintenance inside the RFX-mod2 nuclear fusion machine, where plasma reaches about 20 million °C. ROMAN, developed with University of Naples Federico II’s DII and Herobots, can inspect, clean, and remove or reinstall graphite tiles, with delivery and integration completed for two facilities.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning GNTA (Genenta Science S.p.A.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GNTA coverage spans financial news and technology.
Potential upside for Genenta as its aerospace component gains visibility in European launch missions.
ROMAN is a new, tangible deep-tech milestone tied to Genenta’s ownership and industrial strategy, but it is not quantified financially in the release.
Adds a tangible milestone to Genenta’s industrial-platform narrative, but it is not yet a quantified financial catalyst.
GNTA’s exposure to Sòphia HT is indirect, but the disclosed FY2025 growth and margin expansion can strengthen the investment case and support future consolidation expectations.
Limited direct impact on GNTA's stock price due to absence of shareholder number data. The market is currently closed, and the news does not provide actionable insights for immediate trading decisions.
AlphAI scores every news story that mentions GNTA with an AI model for sentiment and relevance, and aggregates insider trades from Genenta Science S.p.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Genenta (GNTA) announced that its investment, Sòphia High Tech, contributed to the VEGA-C rocket's successful launch, which carried two Earth observation satellites. The Spring Assembly, produced by Sòphia HT, is crucial for stage separation. Genenta is evolving into Saentra Forge, focusing on aerospace and defense.
1 min readGenenta Science (Nasdaq: GNTA) said its backed Italian firm Sòphia High Tech is unveiling ROMAN, a robotic arm for inspection and maintenance inside the RFX-mod2 nuclear fusion machine, which can reach about 20 million °C. ROMAN can remove and reinstall graphite tiles and perform visual inspection and cleaning, developed with DII (Univ. Federico II) and Consorzio RFX.
3 min readGenenta-backed Sòphia High Tech (Italian aerospace and defense) announced ROMAN, a robotic arm for remote inspection and maintenance inside the RFX-mod2 nuclear fusion machine, where plasma reaches about 20 million °C. ROMAN, developed with University of Naples Federico II’s DII and Herobots, can inspect, clean, and remove or reinstall graphite tiles, with delivery and integration completed for two facilities.
3 min readGenenta Science S.p.A. (Nasdaq: GNTA) said its backed company Sòphia High Tech S.r.l. reported FY2025 results approved by Sòphia’s board. Sales rose 29.3% to €7.17m, total value of production to €8.47m, EBITDA to €1.61m and operating profit to €1.21m, with EBITDA margin up to 19.0%. Genenta owns about 19% and may seek up to 51%.
4 min readThe article provides information regarding the number of shareholders for Genenta Science S.p.A., traded on NASDAQ under the symbol GNTA. It indicates that the market is closed and lists various data sources and copyright information. No specific shareholder numbers are presented in the provided content.
1 min readGenenta Science S.p.A. is transforming into Saentra Forge, a strategic industrial consolidator focusing on biotech, defense, aerospace, and technologies critical to Italian national security. While actively exploring collaborations for its original biotechnology platform, the company is not currently in discussions about its biopharmaceutical product Temferon. CEO Pierluigi Paracchi highlighted the importance of retaining valuable technology within Italy and aiming to enhance promising companies through capital and resources to create long-term shareholder value.
3 min readGenenta (Nasdaq: GNTA), transforming into Saentra Forge, has announced a strategic shift to become an industrial consolidator in sectors like biotech, defense, and national security. While the company is exploring collaboration opportunities for its biotechnology platform Temferon with DC Advisory, there are currently no active discussions for partnerships. CEO Pierluigi Paracchi highlighted the founder-scientists' continued shareholdings and the company's focus on selective acquisitions and industrial aggregation to create long-term shareholder value.
3 min readGenenta Science S.p.A. director Sharei Armon has reported initial holdings consisting solely of stock options linked to American Depositary Shares (ADSs) in a Form 3 SEC filing. The holdings include options for 20,163 ADSs at $3.08 (fully vested July 1, 2024), 20,000 ADSs at $4.36 (vesting monthly from June 4, 2025), and 10,000 ADSs at $1.48 (vesting monthly from December 18, 2025). The director holds no direct ordinary shares or ADSs, with all exposure coming from these derivative securities.
2 min readMILAN and NEW YORK, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Genenta Science ( NASDAQ:GNTA ) , a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares ( "ADSs" ) at an offering ...
2 min readMILAN and NEW YORK, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Genenta Science ( Nasdaq: GNTA ) , a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares ( "ADSs" ) at an ...
3 min read
